Beijing Hotgen Biotech Co., Ltd. (688068.SS)
CNY 123.5
(-1.2%)
CNY 123.5
(-1.2%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 27.38 Million CNY | -97.1% |
| 2022 | 944.73 Million CNY | -56.78% |
| 2021 | 2.18 Billion CNY | 1850.41% |
| 2020 | 112.06 Million CNY | 230.8% |
| 2019 | 33.87 Million CNY | -29.63% |
| 2018 | 48.14 Million CNY | 60.08% |
| 2017 | 30.07 Million CNY | 4.42% |
| 2016 | 28.79 Million CNY | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q3 | 2.82 Million CNY | 105.83% |
| 2024 Q2 | -48.52 Million CNY | -1059.93% |
| 2024 Q1 | 5.05 Million CNY | 130.13% |
| 2023 Q1 | 58.88 Million CNY | 132.67% |
| 2023 FY | 27.38 Million CNY | -97.1% |
| 2023 Q4 | -16.77 Million CNY | 44.8% |
| 2023 Q3 | -30.38 Million CNY | -217.4% |
| 2023 Q2 | 25.88 Million CNY | -56.04% |
| 2022 Q1 | 605.96 Million CNY | -14.58% |
| 2022 Q2 | 208.81 Million CNY | -65.54% |
| 2022 Q4 | -180.24 Million CNY | -162.86% |
| 2022 Q3 | 286.73 Million CNY | 37.31% |
| 2022 FY | 944.73 Million CNY | -56.78% |
| 2021 Q3 | 23.72 Million CNY | -97.21% |
| 2021 Q2 | 851.29 Million CNY | 41.57% |
| 2021 Q1 | 601.32 Million CNY | 462.02% |
| 2021 FY | 2.18 Billion CNY | 1850.41% |
| 2021 Q4 | 709.42 Million CNY | 2890.77% |
| 2020 Q4 | 106.99 Million CNY | 3329.21% |
| 2020 FY | 112.06 Million CNY | 230.8% |
| 2020 Q1 | 512.67 Thousand CNY | -97.52% |
| 2020 Q3 | 3.12 Million CNY | 116.55% |
| 2020 Q2 | 1.44 Million CNY | 181.03% |
| 2019 FY | 33.87 Million CNY | -29.63% |
| 2019 Q3 | 1.77 Million CNY | -86.61% |
| 2019 Q2 | 13.29 Million CNY | 820.3% |
| 2019 Q1 | -1.84 Million CNY | -106.26% |
| 2019 Q4 | 20.65 Million CNY | 1060.29% |
| 2018 Q3 | 3.96 Million CNY | 0.0% |
| 2018 FY | 48.14 Million CNY | 60.08% |
| 2018 Q4 | 29.48 Million CNY | 642.69% |
| 2018 Q1 | 3.24 Million CNY | 0.0% |
| 2017 FY | 30.07 Million CNY | 4.42% |
| 2016 FY | 28.79 Million CNY | 0.0% |